Mandate

Vinge advises Smart Eye in a directed new share issue of MSEK 200

May 22, 2019

Vinge has advised Smart Eye AB (Nasdaq First North) on a directed new share issue that provides Smart Eye with approximately MSEK 200.

The subscription price, i.e. SEK 101.50, has been determined by an accelerated book‑building procedure corresponding to a discount of 1.6 per cent compared to the closing price on Nasdaq First North on 21 May 2019. Första AP‑fonden becomes a new major shareholder in the company after having been allotted more than half of the shares in the new issue and thereby becomes the third largest owner with 6.6 per cent of the shares and votes. In total, five major Nordic institutions were allotted approximately 75 per cent of the shares in the new share issue. The purpose of the new share issue is to finance the continued development of the business and an expanded offer towards the Chinese market. Carnegie Investment Bank has acted as sole bookrunner.

Vinge’s team has primarily consisted of responsible partner Anders Strid together with Wibeke Sorling and Edin Agic (Capital Markets), Gu Qun (China Practice), Alexander Lindeberg (IP), Victor Ericsson (Tax) as well as company assistant Camilla Andersson.

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026